Actually---even though "some" people HAVE DIED from this drug, the MS trials continue...
Swiss drugmaker Roche AG and Biogen Idec Inc. are discontinuing development of ocrelizumab in patients with rheumatoid arthritis (RA), after an infection-related safety signal was observed in Phase III testing, resulting in the death of some patients.
A Phase II study of ocrelizumab is ongoing in patients with relapsing remitting multiple sclerosis, and data from that study will be submitted for presentation this fall at the European Committee for the Treatment and Research in Multiple Sclerosis conference in Sweden.
MS patients are just viewed as so lacking in hope or options--what's another deadly infection?
Husband dx RRMS 3/07
dx dual jugular vein stenosis (CCSVI) 4/09
dual stents placed 5/09
CCSVI in MS